Imraldi    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis0
96Crohn disease3

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 4,183 trial found

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04089514
(ClinicalTrials.gov)
June 30, 201912/9/2019A Real-world Study of Imraldi® UsePan-EU Real-World Experience With Imraldi®Arthritis, Rheumatoid (RA);Axial Spondyloarthritis (axSpA);Arthritis, Psoriatic (PsA);Crohn's Disease (CD);Colitis, Ulcerative (UC)Drug: AdalimumabBiogenNULLRecruiting18 YearsN/AAll1400Germany;United Kingdom
2EUCTR2018-004967-30-GB
(EUCTR)
30/04/201914/01/2019Inflammatory Bowel Disease (IBD) Reference product (Humira-adalimumab) and Biosimilar Product (Imraldi-adalimumab) CroSS over StudyIBD Reference and Biosimilar adalimumab CroSS over Study - iBaSS Crohn’s disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Imraldi
Product Name: Imraldi
INN or Proposed INN: adalimumab
Trade Name: Humira
Product Name: Humira
INN or Proposed INN: adalimumab
University Hospital Southampton NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 4United Kingdom
3NCT03662919
(ClinicalTrials.gov)
July 2, 20186/9/2018One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort StudyPERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort StudyArthritis, Rheumatoid;Spondylitis, Ankylosing;Arthritis, Psoriatic;Crohn's Disease;Colitis, UlcerativeDrug: Infliximab;Drug: AdalimumabBiogenNULLRecruiting6 YearsN/AAll3000France